Kenvue Inc. Posts Profit-to-Profit Growth on Both Windows in Interim Filing

Bottom line

Kenvue Inc. delivered a higher top line and higher profitability on both reporting windows in the interim filing identified by 0001944048-26-000142 under 10-Q for period-ended-2026-06-28, with the company ticker KVUE and registrant identifier 0001944048. On the three-month reporting period the three months ended June 28, 2026, revenue rose to $3,955,000,000 from $3,839,000,000 in the prior-year quarter, and on the six-month year-to-date period the six months ended June 28, 2026, revenue rose to $7,864,000,000 from $7,580,000,000 in the prior-year comparative period the six months ended June 29, 2025. Operating profit on the quarter moved up to $699,000,000 from $692,000,000, and on the half-year window moved up to $1,466,000,000 from $1,250,000,000. Net income attributable to the parent on the quarter moved up to $456,000,000 from $420,000,000, and on the half-year window moved up to $930,000,000 from $742,000,000. Diluted earnings per share on the quarter moved up to $0.24 per diluted share from $0.22 per diluted share, and on the half-year window moved up to $0.48 per diluted share from $0.39 per diluted share. All four dimensions cleared the prior year on both windows, and each transition stayed profit-to-profit rather than slipping into a loss. The narrative direction of the filing is therefore unambiguously positive on every line item the catalog covers for this section.

Management framing inside the filing is dominated by forward-looking commentary rather than retrospective explanation, and the cautionary statement treats forward-looking statements as subject to risks, uncertainties, and changes outside the company's control. The same passage references the Separation and the Pending Transaction with Kimberly-Clark, both defined in Note 1 within the Description of the Company and Summary of Significant Accounting Policies. Readers looking for a comparable interim profit-to-profit pattern can contrast this quarter with Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing, which posted a similar direction across the same three dimensions. The interim report structure traverses Items one through six, with legal proceedings and risk factors sitting in Item 1 and Item 1A, market risk and controls in Item 3 and Item 4, and exhibits, signatures, and the cautionary note closing the document in Item 6.

The strength of the directional improvement is consistent across revenue, operating profit, net income, and diluted EPS on both the quarter and the half-year windows, which lowers the chance that a single isolated item is steering the picture. The filing's own commentary, however, leans forward-looking and does not retroactively explain the drivers, so any narrative about why each line item moved is not available in the cited evidence.

No offsetting decline is visible across the four dimensions on either window; revenue, operating income, net income, and diluted EPS are all higher than the prior-period comparative.

UNKNOWN: The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison. The filing evidence does not attribute this change to any single cause.

Financial performance

Reported facts - Revenue from Contract with Customer, Excluding Assessed Tax reached $3,955,000,000 USD in the three months ended June 28, 2026, up from $3,839,000,000 USD in the three months ended June 29, 2025, and aggregated to $7,864,000,000 USD for the six months ended June 28, 2026 versus $7,580,000,000 USD for the six months ended June 29, 2025. - Operating Income (Loss) was $699,000,000 USD for the three months ended June 28, 2026 and $1,466,000,000 USD for the six months ended June 28, 2026, compared with $692,000,000 USD and $1,250,000,000 USD in the respective prior-year windows. - Net Income (Loss) Attributable to Parent came in at $456,000,000 USD for the three months ended June 28, 2026 and $930,000,000 USD for the six months ended June 28, 2026, versus $420,000,000 USD and $742,000,000 USD in the corresponding prior-year windows. - Earnings Per Share, Diluted was $0.24 per diluted share USD/SHARES in the three months ended June 28, 2026 and $0.48 per diluted share USD/SHARES in the six months ended June 28, 2026, against $0.22 per diluted share USD/SHARES and $0.39 per diluted share USD/SHARES in the prior-year windows.

Management explanations - The interim filing, identified as 10-Q period-ended-2026-06-28 for Kenvue Inc. (KVUE, CIK 0001944048, accession 0001944048-26-000142), describes the issuer as organized into three reportable segments — Self Care, Skin Health and Beauty, and Essential Health — and notes that it is a standalone public company carved out from J&J's former Consumer Health business. - Management discloses a Pending Transaction with Kimberly-Clark under a previously announced Merger Agreement, with shareholder approvals secured and certain antitrust waiting periods already expired, while other customary closing conditions and foreign regulatory clearances remain outstanding. - Management flags ongoing Separation-related costs flowing through Cost of sales and Selling, general, and administrative expenses, and describes a global and North America headquarters relocation that was substantially complete as of June of the current fiscal year, with continued legal-entity name-change work and limited other separation activities expected to persist longer than originally planned.

Analyst inference (qualitative, no derived figures) - Both year-over-year comparisons show a higher top line, higher operating result, higher net result and higher diluted earnings per share on the three-month and six-month windows, with each line item remaining profitable against a profitable prior period. - The qualitative pattern of profit-to-profit growth on both windows is consistent with what is described in the related Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows piece, where comparable interim disclosures also posted expansion across revenue, operating income and diluted EPS. - Any read-through from the Pending Transaction with Kimberly-Clark or from Separation-related costs to the magnitude of the quarter-to-date or year-to-date movements cannot be inferred from the disclosure and is therefore not asserted here.

Counter-evidence - No counter-evidence is disclosed in the cited portions of the filing: every comparison window for revenue, operating income, net income attributable to parent, and diluted EPS shows a higher current-period figure than the prior-period figure, without any identified offsetting weakness called out in the source narrative.

Unknowns - Segment-level revenue and segment-level operating income for Self Care, Skin Health and Beauty, and Essential Health are not part of this section's catalog and are not described in the quoted narrative; the direction of any segment contribution to the consolidated movement is therefore not addressed here. - The magnitude of Separation-related costs, the impact of the headquarters relocation, and any restructuring line items under the cited note are not quantified in the quoted passage; the linkage between these items and the year-over-year movements is The filing evidence does not attribute this change to any single cause.. - The filing evidence contains no peer or industry comparison. - Forward guidance ranges, quantitative outlook commentary, and any management-provided full-year EPS or revenue targets are not included in the quoted source narrative and are therefore not asserted in this section.

Operating drivers and segments

The cited note describes three operating segments. The Self Care segment groups cough, cold, and allergy products; pain care; digestive health; smoking cessation; eye care; and other products. The Skin Health and Beauty segment is focused on face and body care, along with hair, sun, and other products. The Essential Health segment covers oral care, baby care, women's health, wound care, and other products. At the consolidated level, the income statement presents Revenue from Contract with Customer, Excluding Assessed Tax of $3,955,000,000 USD for the three-month period the three months ended June 28, 2026 and $7,864,000,000 USD for the six-month period the six months ended June 28, 2026, compared with $3,839,000,000 USD for the three months ended June 29, 2025 and $7,580,000,000 USD for the six months ended June 29, 2025. Operating Income (Loss) was $699,000,000 USD for the three months ended June 28, 2026 and $1,466,000,000 USD for the six months ended June 28, 2026, versus $692,000,000 USD for the three months ended June 29, 2025 and $1,250,000,000 USD for the six months ended June 29, 2025. Both revenue and operating income remain positive on a year-to-date basis. The filing evidence does not attribute this change to any single cause.

Forward-looking commentary in this Form 10-Q identifies several framing themes without quantifying them: future operations, expected operating results and financial performance, the impact of planned acquisitions and dispositions, the strategy for growth and cost savings, product development activities, regulatory approvals, and market position. Management also singles out two structural items — the Separation, which references the previously announced separation of the Consumer Health Business from J&J (acknowledged in the filing's narrative context), and the Pending Transaction with Kimberly-Clark, both defined under Note 1. The cautionary statement further notes that forward-looking remarks depend on assumptions and are subject to risks and uncertainties outside the company's control, and that the Pending Transaction with Kimberly-Clark is not assumed to have closed unless specifically stated.

Cash flow and capital

- Operating cash generation strengthened on a year-over-year basis for the six-month year-to-date period. Net Cash Provided by (Used in) Operating Activities was $1,049,000,000 USD for the six months ended June 29, 2025 and rose to $1,177,000,000 USD for the six months ended June 28, 2026, marking a higher operating cash contribution than the prior-year comparative. The filing evidence does not attribute this change to any single cause.

- Investing activity remained in a use of cash across both windows. Net Cash Provided by (Used in) Investing Activities was -$257,000,000 USD for the six months ended June 29, 2025 and improved (a smaller outflow) to -$245,000,000 USD for the six months ended June 28, 2026, but both periods still represented cash deployment rather than cash generation. - Financing activity continued to absorb cash in both comparative periods.

Net Cash Provided by (Used in) Financing Activities was -$858,000,000 USD for the six months ended June 29, 2025 and widened (a larger outflow) to -$882,000,000 USD for the six months ended June 28, 2026, reflecting the combined drag from capital-return actions and other financing outflows. - Capital spending contracted modestly relative to the prior-year window. Payments to Acquire Property, Plant, and Equipment were $267,000,000 USD for the six months ended June 29, 2025 and stepped down to $203,000,000 USD for the six months ended June 28, 2026, consistent with the cited new global and North America corporate headquarters lease in Summit, New Jersey noted in the filing's narrative.

- The dividend program continued without interruption. Payments of Dividends were $785,000,000 USD for the six months ended June 29, 2025 and increased to $796,000,000 USD for the six months ended June 28, 2026, indicating a higher cash outflow toward shareholders via the dividend channel in the latest six-month window. - Share repurchases presented a notable shift in capital-return emphasis.

Payments for Repurchase of Common Stock were $127,000,000 USD for the six months ended June 29, 2025, whereas the latest six-month year-to-date period shows zero buyback cash use, so the the six months ended June 28, 2026 window reflects no repurchase activity at all. Capital returns in the current year-to-date therefore flowed entirely through dividends rather than buybacks. - On the balance sheet at the balance sheet date of June 28, 2026, liquidity was anchored by Cash and Cash Equivalents, at Carrying Value of $1,110,000,000 USD, while short-term obligations included Accounts Payable, Current of $2,577,000,000 USD.

Together, these line items frame the cash buffer the company carried into the second half of the fiscal year. - Stockholders' equity context is anchored in Note 13, which describes the Preferred stock disclosure framework, while separation-related cost treatment is discussed in Note 15. Restructuring commentary tied to the operating model sits alongside the cash-flow discussion and is referenced for completeness.

The filing evidence does not attribute this change to any single cause. - For analysts triangulating operating-cash and capital-return patterns across recent filings, the year-over-year lift in operating cash paired with a pause in buybacks is a profile echoed in some other consumer-health and pharma interim reports covered under the Lizely Finance earnings series. The filing evidence contains no peer or industry comparison.

Peer and historical context

- The year-over-year direction across both windows for Kenvue Inc. points in the same direction for every reported line on this 10-Q filed for period-ended-2026-06-28 under accession 0001944048-26-000142. - The pattern repeats at both the quarter and the year-to-date windows, which is consistent with a same-store effect rather than a calendar distortion.

- One quarter's result can be skewed by a single large order, a one-time settlement, or an unusual promotional window, so the single-quarter reading should not be read in isolation.

Compared with the prior-year three-month reporting period, Revenue from Contract with Customer, Excluding Assessed Tax was higher than $3,839,000,000 USD and reached $3,955,000,000 USD for the three months ended June 28, 2026. Operating Income (Loss) for that same quarter moved from $692,000,000 USD to $699,000,000 USD, and Net Income (Loss) Attributable to Parent for the three months ended June 28, 2026 rose from $420,000,000 USD to $456,000,000 USD. Each line preserves a profit-to-profit shape, with no swing into a loss.

The same pattern holds at the six-month year-to-date comparison. Revenue from Contract with Customer, Excluding Assessed Tax advanced from $7,580,000,000 USD for the six months ended June 29, 2025 to $7,864,000,000 USD for the six months ended June 28, 2026. Operating Income (Loss) on the year-to-date view moved from $1,250,000,000 USD to $1,466,000,000 USD, and Net Income (Loss) Attributable to Parent moved from $742,000,000 USD to $930,000,000 USD, again profit to profit. Net Cash Provided by (Used in) Operating Activities, the cash conversion counterpart, was higher than the prior-year figure of $1,049,000,000 USD, reaching $1,177,000,000 USD for the six months ended June 28, 2026.

The pull from the prior year to the current period is directionally aligned across revenue, operating profit, net income, and operating cash flow, with no period showing a transition from profit to loss or vice versa. The size of the step is not the same on every line: revenue expansion is the largest in absolute terms, with operating profit, net income, and operating cash flow following the same direction but at varying magnitudes.

Put side by side, the three months ended June 28, 2026 versus the six months ended June 28, 2026 offer a useful cross-check. The quarter's trajectory is consistent with the half-year build, which suggests that the second quarter of the year tracked the first rather than diverging sharply. Readers can compare this multi-line, same-direction pattern with Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing when judging the breadth of the move.

The filing evidence contains no peer or industry comparison. The filing evidence does not attribute this change to any single cause.

Scenario analysis

- Reported facts: Revenue for the three-month reporting period the three months ended June 28, 2026 of Kenvue Inc. was $3,955,000,000 USD, higher than the prior-year comparative of $3,839,000,000 USD. Revenue for the six-month year-to-date period the six months ended June 28, 2026 was $7,864,000,000 USD, higher than the prior-year comparative of $7,580,000,000 USD. Net income attributable to parent for the quarter was $456,000,000 USD, higher than the prior-year $420,000,000 USD, and for the half year was $930,000,000 USD, higher than the prior-year $742,000,000 USD. The filing type is 10-Q for the period-ended-2026-06-28 period under accession 0001944048-26-000142 (CIK 0001944048, ticker KVUE). - Management explanation: The cautionary note Item 6 frames forward-looking statements, and the cited note Note 1 describes the company. The filing does not state a quantified base case. - Analyst inference (cautious): Under a base path the top line continues to grow on both windows at the pace implied by the reported directional changes, while net income stays profitable, consistent with the profit-to-profit transition on both windows. - Counter-evidence: None on the top line; the directional readings are higher on both revenue and net income year-over-year. - Unknowns: The magnitude of any further growth and the contribution of any single segment to that growth are not stated in the filing evidence.

- Reported facts: The same directional readings apply — revenue and net income both higher on the quarter and half-year windows versus the prior-year comparatives. - Management explanation: The cited note Note 15 on restructuring and operating model optimization, together with the cautionary note Item 6, indicates that cost actions are part of the reported mix. The filing evidence does not attribute this change to any single cause. - Analyst inference (cautious): An upside path would entail those optimization efforts continuing to translate into higher reported profit alongside the higher top line, leaving the profit-to-profit transition intact on both windows. - Counter-evidence: Any upside is bounded by the cautionary note's framing of forward-looking statements and by the items covered under Item 4 and Item 1A, including risk factors. - Unknowns: The filing does not provide a quantified upside scenario.

- Reported facts: As above, both revenue and net income are higher on a year-over-year basis for the quarter and the half year. - Management explanation: The cautionary note Item 6 highlights the inherent uncertainty in forward-looking statements, and Item 1A covers risk factors. Legal proceedings are addressed in Item 1. - Analyst inference (cautious): A downside path would involve the trends implied by the reported directional readings reversing, with the cited restructuring and operating model optimization efforts not offsetting other pressures; the current evidence does not describe such a reversal. - Counter-evidence: The reported year-over-year increases on revenue and net income on both windows cut against a near-term downside narrative. - Unknowns: The filing does not quantify a downside scenario. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Risks and what to watch

- Reported facts (from the filing): Revenue from Contract with Customer, Excluding Assessed Tax came in at $3,955,000,000 for the three months ended June 28, 2026 and at $7,864,000,000 for the six months ended June 28, 2026. The corresponding prior-year comparatives were $3,839,000,000 (the three months ended June 29, 2025) and $7,580,000,000 (the six months ended June 29, 2025), both moving higher year over year on each window. Net Income (Loss) Attributable to Parent was $456,000,000 for the three months ended June 28, 2026 and $930,000,000 for the six months ended June 28, 2026, against prior-year comparatives of $420,000,000 and $742,000,000, again higher on each window.

- Management explanations: The Company flags that it is "currently evaluating" two recently issued FASB updates — ASU on internal-use software (capitalization guidance) and ASU on hedge-accounting improvements — and notes "the impact on its financial statements and related disclosures" is still being assessed. No other new accounting standards became effective during the fiscal six months, and the Company adds the customary cautionary statement under Item 6. - Analyst inference: The transition in revenue and net income across both the three-month and six-month windows is profit-to-profit with rising direction on every line, while the structure of the period (a half-year report) means that interim accounting-policy adoption effects, if any, would still be sitting inside the reported numbers.

The disclosure that the Company is still evaluating the two ASUs is the clearest forward-looking signal in the narrative. - Counter-evidence and unknowns: The Company acknowledges pending accounting-standard evaluation without quantifying any prospective impact, and the income-statement and revenue lines do not separate out the effect, if any, of these adoptions. Information that would normally help stress-test the result — segment-level organic growth, price/volume mix, currency translation drag, restructuring run-rate under Note 15, or peer comparison data — is not provided in the cited evidence.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. - NEXT WATCH (metrics to track next period): (i) any explicit disclosure on adoption timing and financial-statement effect of the internal-use software and hedge-accounting ASUs; (ii) the restructuring and operating-model optimization roll-forward under Note 15; (iii) revenue and net income for the next three-month period relative to $3,839,000,000 and $420,000,000 to confirm whether the year-over-year direction holds; (iv) any updates under Item 1A risk factors, Item 3 market-risk disclosures, and Item 4 controls and procedures that could change the interpretation of the trend; and (v) capital-return activity, given that share repurchases compared with the prior the six months ended June 29, 2025 period and dividends moved in the authorized direction in the cash-flow statement.

Readers comparing patterns across issuers can contrast the directional set with Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing for a same-window cross-check.